Trial Profile
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and Graft-versus-host Disease in Allogeneic Hematopoietic Cell Transplantation for High-risk Hematologic Malignancies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Busulfan; Fludarabine; Melphalan; Methotrexate; Tacrolimus
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 19 Jan 2021 Status changed from active, no longer recruiting to completed.
- 17 Apr 2019 Planned End Date changed from 1 Mar 2019 to 1 Oct 2020.
- 31 May 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.